Sandoz Does Not Budge On 2022 Expectations Despite Positive Start
Q1 Revenues Improve By 8% At CCs While Bottom Line Soars – With Caveats
Executive Summary
A weak base for the prior year and several one-time items allowed Sandoz to post positive financial results for the first quarter of 2022, including a 26% jump in the company’s core operating profit. Electing not to upgrade its expectations for Sandoz this year, Novartis will continue to monitor the business amid an ongoing strategic review.
You may also be interested in...
Sandoz Says All Options Still Open After Spinoff Rumors
Sandoz has responded to recent rumors that parent company Novartis is favoring a spinoff of the generics and biosimilars business over a sale or retention, insisting that “all options remain open” as a strategic review of the unit continues.
Can The Pipeline Soothe A US Generics Pricing Headache?
Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.
Can The Pipeline Soothe A US Generics Pricing Headache?
Following a year marked by aggressive pricing pressures weighing down on revenues and margins – pressures that “intensified beyond historical norms and our recent expectations,” as one company put it – the first quarter of 2022 provided some green shoots of optimism, albeit for companies that have been able to shift resources to more complex assets.